Prognostic V alue o f KIT Mutation T ype, M itotic A ctivity, and H istologic S ubtype i n G astrointestinal S tromal Tumors

Samuel Singer(Memorial Sloan Kettering Cancer Center), Jonathan A. Fletcher(Harvard University), Brian P. Rubin(Cleveland Clinic), Marcia L. Lux(Brigham and Women's Hospital), George D. Demetri(Dana-Farber Cancer Institute), Changjie Chen(Bengbu Medical College)
Unknown
January 1, 2002
Cited by 0

Related Papers

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996